TCGA-78-8655-01A-11R-2403-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.410
- NOTCH_SIGNALING+0.380
- TGF_BETA_SIGNALING+0.360
- IL6_JAK_STAT3_SIGNALING+0.350
- INTERFERON_GAMMA_RESPONSE+0.340
- ALLOGRAFT_REJECTION+0.300
- COMPLEMENT+0.260
- COAGULATION+0.210
- KRAS_SIGNALING_UP+0.210
- INFLAMMATORY_RESPONSE+0.170
Top 10 suppressed
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.510
- MTORC1_SIGNALING-0.480
- MYC_TARGETS_V1-0.420
- SPERMATOGENESIS-0.350
- UNFOLDED_PROTEIN_RESPONSE-0.350
- CHOLESTEROL_HOMEOSTASIS-0.330
- MYC_TARGETS_V2-0.330
- HYPOXIA-0.300
- HEDGEHOG_SIGNALING-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-95-8039-01A-11R-2241-07 | — | cohortA1 | 0.846 |
| 2 | SRR8942946 | — | — | 0.836 |
| 3 | SRR8943004 | — | — | 0.832 |
| 4 | 0bdec778-829d-4cba-8d0f-dcaa0d8803b1 | — | — | 0.824 |
| 5 | C3N-02451 | — | cohortA1 | 0.816 |
| 6 | SRR8518288 | — | A | 0.816 |
| 7 | C3L-00973 | — | cohortA1 | 0.812 |
| 8 | TCGA-86-8280-01A-11R-2287-07 | — | cohortA1 | 0.798 |
| 9 | SRR1516086 | — | — | 0.797 |
| 10 | TCGA-44-3919-01A-02R-1107-07 | — | cohortA1 | 0.797 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.070 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.010 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.010 | Inavolisib | — uncovered |